{
    "2018-08-23": [
        [
            {
                "time": "",
                "original_text": "龙头股仍受青睐，多只个股回调获加仓",
                "features": {
                    "keywords": [
                        "龙头股",
                        "回调",
                        "加仓"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德上市后首份半年报：营收44亿，净利润同比增长32%",
                "features": {
                    "keywords": [
                        "药明康德",
                        "半年报",
                        "营收",
                        "净利润",
                        "增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药独角兽有毒 股民和社保基金纷纷被套",
                "features": {
                    "keywords": [
                        "医药",
                        "独角兽",
                        "股民",
                        "社保基金",
                        "被套"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "药明康德利润“华而不实”？理财产品投资额激增97倍",
                "features": {
                    "keywords": [
                        "药明康德",
                        "利润",
                        "理财产品",
                        "投资额",
                        "激增"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【财通医药】药明康德(603259)：业绩超预期，三驾马车齐发力",
                "features": {
                    "keywords": [
                        "药明康德",
                        "业绩",
                        "超预期",
                        "三驾马车",
                        "发力"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德:研发高投入叠加股权激励 能否带来高成长？",
                "features": {
                    "keywords": [
                        "药明康德",
                        "研发",
                        "高投入",
                        "股权激励",
                        "高成长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}